Chemoembolization Plus Ablation: Current Status

Farnaz Dadrass, Pascal Acree, Edward Kim

Research output: Contribution to journalArticlepeer-review


Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. The treatment landscape for HCC has evolved significantly over the past decade, with several modalities available to treat various stages of disease. The Barcelona Clinic Liver Cancer (BCLC) system provides a foundation for treatment guidance. However, given the complex nature of HCC, a more nuanced approach is often required, especially for lesions sized between 3 and 5 cm. This review aims to analyze the available treatments for early-stage HCC lesions between 3 and 5 cm, with a focus on the therapeutic potential and efficacy of transarterial chemoembolization (TACE)-ablation. Additional therapies including TACE, ablation, transarterial radioembolization, and surgical resection are also reviewed and compared with TACE-ablation. TACE-ablation is a viable therapeutic option for early-stage HCC lesions between 3 and 5 cm. Surgical resection remains the gold standard. Although recent studies suggest radiation segmentectomy may be a curative approach for this patient population, further studies are needed to compare the relative efficacies between TACE-ablation and radiation segmentectomy.

Original languageEnglish
Pages (from-to)505-510
Number of pages6
JournalSeminars in Interventional Radiology
Issue number6
StatePublished - 2024


  • TACE-ablation
  • ablation
  • chemoembolization
  • hepatocellular carcinoma
  • interventional oncology
  • interventional radiology


Dive into the research topics of 'Chemoembolization Plus Ablation: Current Status'. Together they form a unique fingerprint.

Cite this